Drug Profile
Nadolol - Invion
Alternative Names: INV 102; INV102 controlled release; INV102 CRLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Inverseon
- Developer Chronic Airway Therapeutics; Invion
- Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Propanolamines; Small molecules
- Mechanism of Action Beta adrenergic receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease
Highest Development Phases
- Phase II Asthma; Smoking withdrawal
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 22 Feb 2023 Nadolol is still in preclinical development in Chronic-obstructive-pulmonary-disease in USA (PO, Capsule) (Chronic Airway Therapeutics pipeline, February 2023)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (PO, Capsule)
- 26 Sep 2017 Nadolol is still at phase II development stage for Asthma and Smoking withdrawal in USA (PO) (Invion Annual report, June 2017)